ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
|Articles|March 14, 2019
Stream Bio Launches Nano Bioimaging Probes in Italy
Author(s)BioPharm International Editors
Stream Bio entered into a new agreement with DBA Italia to launch Stream Bio’s nanotech-based bioimaging probes in Italy.
Advertisement
On March 12, 2019, Stream Bio, a developer and manufacturer of innovative bioimaging molecular probes, entered into a new agreement with DBA Italia, a supplier of research reagents for immunology, biochemistry, cellular, and molecular biology, to launch Stream Bio’s nanotech-based bioimaging probes in Italy.
The agreement expands Stream Bio’s European distribution network for its Conjugated Polymer Nanoparticles (CPNs), which represent a new generation of novel molecular bioimaging probes. These nanoparticles are highly fluorescent and non-toxic, offering stability, magnetic capability, and suitability to be conjugated with a wide range of molecules.
The launch highlights the continued growth and commercial potential of the CPNs. Stream Bio also recently received an Innovate UK-funded manufacturing and materials loan, which will enable the further expansion of its product range.
The CPNs come in four emission wavelengths ranging from 475–680 nm and can now be streptavidin-linked. Applications for these probes include diagnostics and therapeutics and the potential to be used for imaging tumors and fluorescence-guided surgery. They are already distributed in the United Kingdom and Ireland through 2BScientific, in France through CliniSciences, and in Germany through Biotrend.
Source:
Advertisement
Related to this article
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5